Under construction – not a live service
Sign in
Taking people in SwedenNo phase

Tests blood and brain markers for memory problems in primary care

Tests blood markers and brain scans to detect Alzheimer disease in adults with memory concerns.

Key facts

Who runs it
Skane University Hospital
Where
Malmö, SwedenSee the site
Trial code
Registry title
The Swedish BioFINDER - Primary Care Study
Status
Recruiting
People taking part
1,200 people, planned
Started
1 Jan 2020
Expected to end
31 Dec 2028
Type of study
Observational
Treatments tested
  • Plasma APS 2 score
  • Plasma p-tau217/np-tau217
  • Plasma p-tau217
  • Plasma neurofilament light (NfL)
  • Plasma Ab42/Ab40
  • MRI and CT of the brain
  • Different cognitive tests
Record updated
6 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older who see a doctor in primary care because of memory or thinking problems. It includes people with subjective cognitive decline, mild cognitive impairment or mild dementia.

Age
40 years and older
Sex
All sexes can join
Disease stage
Subjective cognitive decline, mild cognitive impairment or mild dementia. The main symptom is usually memory problems, but other thinking problems also count.

Main reasons for not taking part

  • Already diagnosed dementia
  • Significant unstable illness or organ failure that makes taking part difficult
  • Current significant alcohol or substance misuse
  • Refusing investigation at the Memory clinic
  • Thinking problems with sudden onset due to stroke

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • The patient seeks medical help because of cognitive symptoms experienced by the patient and/or informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment
  • The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints
  • Age ≥40 years
  • Subjective cognitive decline, mild cognitive impairment or mild dementia

Who cannot take part

  • Already diagnosed dementia
  • Significant unstable systemic illness or organ failure that makes it difficult to participate
  • Cognitive impairment with acute onset due to stroke
  • The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc
  • Current significant alcohol or substance misuse
  • Refusing investigation at the Memory clinic

Where in Sweden

  • Primary care centers in Region SkåneMalmö, SwedenContact: Sebastian Palmqvist, MD, PhDTaking people

About the trial

What the trial wants to find out

The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:

Read full original descriptionShow less

1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care. 2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care. 3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care. 4. Determine whether blood AD biomarkers improve patient management in primary care.

The group in the trial

  • Patients in primary care with cognitive symptoms

    Treatment: Plasma APS 2 score, Plasma p-tau217/np-tau217, Plasma p-tau217, Plasma neurofilament light (NfL), Plasma Ab42/Ab40, MRI and CT of the brain, and Different cognitive tests

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Swedish BioFINDER - Primary Care Study
Plain-language title
Tests blood and brain markers for memory problems in primary careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 April 2026